Mkts

Keros Therapeutics, Inc.

NASDAQ: KROS
$9.17-0.19 (-2.03%)
As of Nov 9, 4:00 PM ET

Key statistics

Day range
9.109.87
52-week range
9.2622.55
Today
Open9.50
Previous close9.17
Volume—
Valuation
Market cap185.84M
P/E ratio—
EPS (TTM)-3.70
Income & risk
Dividend / yield—
Beta1.23
Avg volume192.4K
Discussion

KROS News

Stories mentioning KROS from around the web — every one is an open thread, so give it a like or add your take.

All news →

Loading news…

Financial statements

Financial statements

As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.

Line itemQ1 '26Mar 31Q4 '25Dec 31Q3 '25Sep 30Q2 '25Jun 30Q1 '25Mar 31Q4 '24Dec 31Q3 '24Sep 30Q2 '24Jun 30
Income Statement
Revenue367.00385.0014,26218,168211,2463,042388.0037.00
Cost of Goods Sold
Gross Profit
Operating Expenses
Research & Development16,09717,91219,51943,50348,70945,63149,22540,515
Sales General & Admin
Total Operating Expenses26,24429,65529,64657,98559,20656,29659,04550,476
Operating Income (Loss)(25,877)(29,270)(15,384)(39,817)152,040(53,254)(58,657)(50,439)
Interest Income
Interest Expense
Other Expense(166.00)273.00(253.00)(221.00)(338.00)(229.00)(92.00)(196.00)
Pretax Income(23,708)(24,975)(8,704)(32,918)158,494(45,726)(52,956)(45,257)
Tax Provision0.00(1,514)(1,424)(2,222)10,043300.000.000.00
Net Income (Loss)(23,708)(23,461)(7,280)(30,696)148,451(46,026)(52,956)(45,257)
Earnings Per Share (Basic)(1.21)(0.63)(0.18)(0.76)3.66(1.23)(1.41)(1.25)
Earnings Per Share (Diluted)(1.21)(0.62)(0.18)(0.76)3.62(1.23)(1.41)(1.25)
Weighted Average Shares Outstanding (Basic)19,63037,22140,62340,61340,55937,43837,59136,103
Weighted Average Shares Outstanding (Diluted)19,63037,85940,62340,61341,02137,43837,59136,103

Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.

Key facts

About KROS

Keros Therapeutics, Inc. (NASDAQ: KROS) is a stock listed on the Nasdaq Stock Market under the ticker symbol KROS. It last traded at $9.17 (Nov 9, 2026, 4:00 PM ET), down 2.0% on the day. That gives Keros Therapeutics a market capitalisation of $185.8M.

Over the past 52 weeks KROS has traded between $9.26 and $22.55.

Revenue for the quarter ended Mar 31, 2026 was $367.0K; a net loss of $23.7M. Revenue was down 99.8% from $211.2M in the quarter ended Mar 31, 2025.

Last 4 quarters
Quarter endedRevenueNet incomeMargin
Mar 31, 2026$367.0K-$23.7M-6459.9%
Dec 31, 2025$385.0K-$23.5M-6093.8%
Sep 30, 2025$14.3M-$7.3M-51.0%
Jun 30, 2025$18.2M-$30.7M-169.0%

From Keros Therapeutics’s quarterly (10-Q) filings, in US dollars.

Latest News

Market news from around the web — every story is an open thread, so give it a like or add your take.

All news →

Loading news…